Topoisomerase I inhibitors and drug resistance

Cytotechnology

Volumn 27, Issue 1-3, 1998, Pages 149-164

  Parchment, Ralph E ^a,b   Pessina, Augusto ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Camptothecin; Drug resistance; Topo I inhibitors; Topoisomerase I

Indexed keywords

CAMPTOTHECIN; CANCER THERAPY; CYTOTOXICITY; DRUG RESISTANCE; ENZYME INHIBITOR; SINGLE STRAND BREAK; TOPOISOMERASE I INHIBITOR;

EID: 0032443444     PISSN: 09209069     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-017-2374-9_9     Document Type: Article

References (180)

1. Abigerges D, Armand JP, Chabot GG, Bruno R, Bissery MC, Bayssas M, Klink-Alakl M, Clavel M and Catimel G (1996) Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients. Anticancer Drugs 7: 166-74.
2. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kuzunoki Y, Takemoto Y and Okada K (1987) Characterization of a mammalian mutant with camptothecin resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-69.
3. Andrews BJ (1992) Gene expression-dialogue with the cell cycle. Nature 355: 393-1
4. Baguley BC, Holdway KM and Fray LM (1990) Design of DNAintercalators to overcome topoisomerase II-mediated multidrug resistance. J Natl Cancer Inst 82: 398-302.
5. Baker SD, Wadkins RM, Stewart CF, Beck WT and Danks MK (1995) Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry 19: 134-45.
6. Barrett JF, Sutcliffe YA and Gootz TD (1990) In vitro assay used to measure the activity of topoisomerases. Antimicrob. Agents Chemother34: 1-7.
7. Barronco SC (1984) Cellular and molecular effects of Adriamycin on dividing and non dividing cells. Pharmac Ther 24: 303-319.
8. Beck WT (1987) The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2879-88.
9. Beck WT and Danks MK (1991) Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin Cancer Biol 2: 235-44.
10. Beck WY Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP and Trent JM (1987) Pharmacological molecular and cytogenetic analysis of 'atypical' multidrug-resistant human leukemic lines. Cancer Res 47: 5455-60.
11. Beidler DR and Cheng YC (1995) Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 47: 907-14.
12. Besterman JM (1996) Topoisomerase I inhibition by the camptothecin analog Gil47211C. From the laboratory to the clinic. Ann N Y Acad Sci 803: 202-9.
13. Boege F, Straub T, Kehr A, Boesenberg C, Christiansen K, Andersen A, Jakob F and Kohrle J (1996) Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. J Biol Chem 271: 2262-70.
14. Bronstein IB, Vorobyev S, Timofeev A, Jolies CJ, Alder SL and Holden JA (1996) Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. One Res 8: 17-25.
15. Buckwalter CA, Lin AH and Tanizawa A et al. (1996) RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res 6: 1674-81.
16. Burke TG and Mi Z (1993) Preferential binding of carboxylate form of camptothecin by human serum albumin. Analytical Biochem 21: 285-87.
17. Burke TG and Mi Z (1994) The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability. JMedChem37:401-6.
18. Carrigan SW, Fox PC, Wall ME, Wani MC and Bowen JP (1997) Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents. J Comput Aided Mol Des 11: 71-8.
19. Champoux JJ (1981) DNA is linked to the rat liver nicking-closing enzyme by a phosphodiester bond to tyrosine. J Biol Chem 256: 4805-09.
20. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC and Liu LF (1991) Camptothecin overcomes MDRl-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039-6044.
21. Chen AY, Yu C, Bodley A, Peng LF and Liu LF (1993) A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res 53: 1332-37.
22. Chin KV, Pastan I and Gottesman MM (1993) Function and regulation of the human multidrug resistance gene. Adv. Cancer Res 60: 157-80.
23. Chin KV, Ueda K, Pastan I and Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255: 459-62.
24. Clynes M (1993) Cellular models for multiple drug resistance in cancer. In Vitro Cell. Dev Biol 29A: 171-79.
25. Clynes M, Redmond A and Heenan M (1990) Recent developments in research on multiple drug-resistance in cancer cells. Cancer J 3: 34-39.
26. Cobb J, Reddy RK, Park C and Handel MA (1997) Analysis of expression and function of topoisomerase I and II during meiosis in male mice. Mol Reprod Develop 46: 489-98.
27. Creemers GJ, Lund B and Verweij J (1994) Topoisomerase I inhibitors: Topotecan and Irinotecan. Cancer Treatment Rev 20: 73-96.
28. Cummings J, Macpherson JS, Meikle I and Smyth JF (1996) Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance. Biochem Pharmacol 52: 979-90.
29. Dahut W, Brillhart N, Takimoto C, Allegra C, Hamilton JM, Sorensen JM, Arbuck S, Chen A and Grem J (1994) A phase I trial of 9-aminocamptothecin (9-AC) in adult patients with solid tumors. Proc Am Soc Clin Oncol 13: A345.
30. Danks MK, Garret KE and Marion RC et al. (1996) Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res 56: 1664-73.
31. D'arpa P and Liu FL (1989) Topoisomerase-targeting antitumor-drugs. Biochim Biophis Acta 989: 163-77.
32. Deady LW, Kaye AJ, Finlay GJ, Baguley BC and Denny WA (1997) Synthesis and antitumor properties of N-[2(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. J Med Chem 40: 2040-6.
33. Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, SheaTC, Henner WD and Geldenberg GJ (1988) Multifactorialresistance to Adriamycin: relationship of DNA repair, glutathione transferase activity drug efflux, and P-glycoprotein in cloned cell lines of Adriamycin-sensitive and resistant P388 leukemia. Cancer Res 48: 3595-602.
34. Endicott JA and Ling V (1989) The biochemistry of P-glycoproteinmediated multridrug resistance Annu Rev Biochem 58: 351-375.
35. Eng WK, Faucette L, Johnson RK and Sternglanz R (1988) Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34: 755-60.
36. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP and Johnson RK (1990) Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38: 471-80.
37. EORTC (1992) Reports on Topoisomerase I Inhibitors from the 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, March 17-20.
38. Erickson-Miller CL, May RD, Tomaszewski JE, Osborn B, Murphy MJ, Page JG and Parchment RE (1997) Differential toxicity of camptothecin, topotecan, and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Can Chem Pharmacol 39: 467-72.
39. Ferguson PJ, Fisher MH, Stephenson J, Li D-H, Zhou B-S and Cheng Y-C (1988) Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48: 5956
40. Fojo AT, Ueda K, Slamon DJ, Poplank DG, Gottesman MM and Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269.
41. Friedman HS, Houghton PJ, Schold SC, Keir S and Bigner DD (1994) Activity of 9-dimethlyaminomethyl-10hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34: 171-74.
42. Fujimori A, Gupta M, Hoki Y and Pommier Y (1996) Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. Mol Pharmacol 50: 1472-8.
43. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M and Saijo N (1996) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 56: 789-93.
44. Funabashi Y, Horiguchi T, linuma S, Tanida S and Harada S (1994) TAN-1496 A, C and E, diketopiperazine antibiotics with inhibitory activity against mammalian DNA topoisomerase I. J Antibiot47: 1202-18.
45. Funayama Y Nishio K, Wakabayashi K, Nagao M, Shimoi K, Ohira T, Hasegawa S and Saijo N (1996) Effects of beta- and gammacarboline derivatives of DNA topoisomerase activities. Mutat Res 349: 183-91.
46. Geliert M (1981) DNA topoisomerases. Annu Rev Biochem 50: 879-910.
47. Germann UA (1996) P-glycoprotein- A mediator of multidrug resistance in tumor cells. Eur J Cancer 6: 927-944.
48. Gerrits CJ, Creemers GJ, Schellens JH, Wissel P, Planting AS, Kunka R, Selinger K, de Boer-Dennert M, Marijnen Y, Harteveld M and Verweij J (1996) Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. Br J Cancer 73: 744-50.
49. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-48.
50. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R and Potmesil M (1991) Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51: 3052-55.
51. Gobert C, Bracco L, Rossi F, Olivier M, Tazi J, Lavelle, Larsen AK and Riou JF (1996) Modulation of DNA topoisomerase I activity by p53. Biochem 35: 5778-86.
52. Gottlieb JA, Guarino AM, Call JB, Oliverio VT and Block JB (1970) Preliminary pharmacologie and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Reports 54: 461-70.
53. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC and Noe DA (1992) Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Disp 20: 706-13.
54. Gromova II, Kjeldsen E, Svejstrup JQ, Aisner J, Christiansen K and Westergaard O (1993) Characterization of an altered DNA catalysis of a camptothecin resistant eukaryotic topoisomerase I. Nucleic Acid Res 21: 593-600.
55. Gupta E, Lestingi TM, Mick R, Ramirez J, Yokes EE and Ratain Ml (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54: 3723-5.
56. Gupta M, Abdel-Megeed M, Hoki Y, Kohlhagen G, Paull K, and Pommier Y (1995) Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517. Mol Pharmacol 48: 658-65.
57. Gupta RS, Gupta R, Eng B, Lock RB, Ross WE, Hertzberg RP, Caranfa MI and Johnson RK (1988) Camptothecin resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48: 6404-10.
58. Hait WN and Aftab DT (1992) Rational design and preclinical pharmacology of drugs for reversing multidrug resistance. Biochem Pharmacol 43: 103-7.
59. Heck MMS, Hittelman WN and Earnshaw WC (1988) Differentialexpression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85: 1086-90.
60. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC and Kaufmann SH (1992)Effect of p-glycoprotein expression of the accumulation and cytotoxicity of topotecan (SK&f 104864) a new camptothecin analogue. Cancer Res 52: 2268-70.
61. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ and Blum RH (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12: 553-59.
62. Hoki Y, Fujimori A and Pommier Y (1997) Differential cytotoxicity of clinically important camptothecin derivatives in Pglycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol 40: 433-8.
63. Horwitz SB (1975) Antibiotics In: Mechanism of action of antimicrobial and antitumor agents. Corcoran W and Hahn FE (eds) Vol III, pp. 48-57, N.Y, Springer Verlag.
64. Horwitz SB and Horwitz MS (1973) Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 33: 2834-36.
65. Houghton PJ, Cheshire PJ, Myers I, Stewart CF, Synold TW and Oughton JA (1992) Evaluation of 9-dimethylaminomethyl10-hydroxycamptothecin against xenografts derived from adult and chidhood solid tumors. Cancer Chemother Pharmacol 31: 229-59.
66. Hsiang H, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R and Potmesil M (1989) DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49: 4385-89.
67. Hsiang T-S (1992) DNA Topoisomerases. Curr Opin Cell Biol 4: 396-400.
68. Hsiang YH, Herzberg R, Hecht S and Liu LF (1985) Camptothecin induces protein linked DNA breaks via mammalian DNA topoisomerases J Biol Chem 260: 14873-78.
69. Hsiang YH, Lihou MG and Liu LF (1989a) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-82.
70. Hsiang YH, Wu HY and Liu FL (1988) Proliferation dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 48: 3230-35.
71. Husain I, Mohler JL, Seigler HF and Besterman JM (1994) Elevation topoisomerase I messenger RNA, protein and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54: 539-46.
72. Hussy P, Maass G, Tümmler B, Grosse F and Schomburg U (1986) Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase α primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother 29: 1073-78.
73. Ikuno N, Soda H, Watanabe M and Oka M (1995) Irinotecan (CPT11) and characteristic mucosal changes in the mouse ileum and cecum (see comments). J Natl Cancer Inst 87: 1876-83.
74. Ishii K, Futaki S, Uchiyama H, Nagasawa K and Andoh T (1987) Mechanism of inhibition of mammalian DNA topoisomerase I by heparin. Biochem J 241: 111-16.
75. Ishimi Y Nishizawa M and Andoh T (1991) Characterization of a camptothecin-resistant human DNA topoisomerase I in an in vitro system for Simian virus 40 DNA replication. Eur J Biochem 202: 835-39.
76. Izquierdo MA, Scheffer GL, Flens MI, Schroeijers AB, van der Valk P and Scheper RJ (1996) Major vault protein LRP-related multidrug resistance. Eur J Cancer 6: 976-84.
77. Jaxel C, Kohn KW, Wani MC, Wall ME and Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465-69.
78. Jaxel C, Capranico G, Wasserman K, Kerrigan D, Kohn KW and Pommier Y (1991) DNA sequence at sites of topoisomerase I cleavage induced by Camptothecin in SV40 DNA. In: Potmesil M and Kohn KW (eds) DNA topoisomerases in cancer. Oxford University Press, New York, pp. 182-195.
79. Jensen PB, Holm B, Sorensen M, Christensen IJ and Sehested M (1997) In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 75: 869-77.
80. Juan CC, Hwang J, Liu AA, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Zhang H, Wang JC and Liu LF (1988) Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20ql2-13.2. Proc Natl Acad Sci USA 85: 8910-17.
81. Kafiani CA, Bronstein IB, Timofeen AV, Gromova II and Terskikh VV (1986) DNA topoisomerases and regulation of cell proliferation. Adv Enzyme Regul 25: 439-57.
82. Kantaijian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating Ml and Estey EH (1993) Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81: 1146-51.
83. Kanter PM and Schwartz HS (1982) A fluorescence enhancement assay for cellular DNA damage. Mol Pharmacol 22: 145-51.
84. Kanzawa F, Sugimoto Y and Minato K, et al. (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small-cell lung cancer: Characterization and mechanism of resistance. Cancer Res 50: 5919-24.
85. Khon KW, Ewig RAG, Erickson LC and Zwelling LA (1981)Measurement of strand breaks and cross links by alkaline elution. In: Friedberg EC and Hanawalt PC (eds) DNA repair: a laboratory manual of research procedures, (pp. 379-401) Marcel Dekker, Inc. New York.
86. Kirn JS, Gatto B, Yu C, Liu A, Liu LF, and La Voie EJ (1996) Substituted 2, S'-Bi-lH-benzimidazoles: topoisomerase I inhibition and cytotoxicity. J Med Chem 39: 992-8.
87. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK and Hertzberg RP (1991) Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98-107.
88. Kjeldsen E, Bonven BJ, Andoh T, Ishii K, Okada K, Bolund L and Westergaard O (1988) Characterization of a camptothec in resistant human DNA topoisomerase I. J Biol Chem 263: 3912-16.
89. Knab AM, Fertala J and Bjornsti MA (1993) Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. J Biol Chem 268: 22322-30.
90. Kubota N, Kanzawa F, Nishio K, Takeda Y, Ohmori T, Fujiwara Y Terashima Y and Saijo N (1992) Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem Biophys Res Commun 188: 571-7.
91. Lefevre D, Riou J-F and Ahomadegbe JC et al. (1991) Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and the acidic glutathione S transferase. Biochem Pharmacol 41: 1967-79.
92. Li HL, Fraser TJ, Olin EJ and Bhuyan BK (1972) Action of camptothecin on mammalian cells in culture. Cancer Res 32: 2643-50.
93. Lin JH and Castora FJ (1995) Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and mAMSA. Arch Biochem Biophys 324: 293-9.
94. Liu LF (1983) DNA topoisomerase-enzymes that catalyse thebreacking and rejoining of DNA. Crit Rev Biochem 15: 1-24.
95. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-75.
96. Liu LF (1990) DNA topoisomerases in drug resistance and cancer chemotherapy. The third Conference on DNA Topoisomerase in therapy. Oct 15-18, New York, p. 25.
97. Liu LF, Rowe TC, Yang L, Tewey KM and Chen GL (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258: 15365-70.
98. Loe DW, Deeley RG and Cole SPC (1996) Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 6: 945-57.
99. Ludescher C, Gattringer C, Drach J, Hofmann J and Grunicke H (1991) Rapid functional assay for the detection of multidrugresistant cells using the fluorescent dye rhodamine-123. Blood 78: 1385-87.
100. Madden KR, Stewart L and Champoux JJ (1995) Preferential binding of human topoisomerase I to superhelical DNA. EMBO J 14: 5399-109.
101. Makhey D, Gatto B, Yu C, Liu A, Liu LF and La Voie EJ (1996) Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Bioorg Med Chem 4: 781-91.
102. Marshall ES, Finlay GJ, Matthews JHL, Shaw JHF, Nixon J and Baguley BC (1992) Microculture-based chemosensitivity testing: a feasibility study camparting freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst84: 341-44.
103. Masin JS, Berger SJ, Setrakian S, Stepnik DW and Berger NA (1995) Topoisomerase I activity in squamous cell carcinoma of the head and neck. Laring 105: 1191-6.
104. McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D, van der Zee AGJ, Kaye SB, Brown R and Keith WN (1994) Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 59: 607-611.
105. Meikle I, Cummings J, Macpherson JS and Smyth JF (1995) Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs. Anticancer Drug Des 10: 515-27.
106. Mi Z and Burke TG ( 1994a) Differential interaction of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33: 10325-36.
107. Mi Z and Burke TG (1994b) Marked interspecies variations concerning the interaction of camptothecin with serum albumin: a frequency-domain fluorescence spectroscopic study. Biochemistry 33: 12540-45.
108. Muggia FM, Creaven PJ, Hansen H, Cohen MH and Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Reports 56: 515-21.
109. Muller MT, Pfund WP and Mehta VB et al. (1985) Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J 4: 1237-43.
110. Murren JR, Beidler DR and Cheng YC (1996) Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks. Ann N Y Acad Sci 803: 74-92.
111. Nakatsu S, Kondo S, Kondo Y, Yin D, Peterson JW, Kaakaji R, Morimura T, Kikuchi H, Takeuchi J and Barnett GH (1997) Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 39: 417-23.
112. Niimi S, Nakagawa K, Sugimoto Y Nishio K, Fujiwara Y Yokoyama S, Terashima Y and Saijo N (1992) Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 52: 328-33.
113. Nitiss JL and Beck WT (1996) Antitopoisomerase drug action and resistance. Eur J Cancer 6: 958-66.
114. Nooter K and Herweijer H (1991) Multidrug resistance (mdr)genes in human cancer. Br J Cancer 63: 663-9.
115. Oguro M, Seki Y Okada K and Andoh T (1990) Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)resistant cell lines. Biomed Pharmacother 44: 209-216.
116. Pantazis P, Early JA, Mendoza JT, DeJesus AR and Giovanella BC (1994a) Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res 54: 771-6.
117. Pantazis P, Harris N, Mendoza J and Giovanella B (1994b) Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro (letter). Eur J Haematol 53: 246-8.
118. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ Jr, Stehlin JS Jr and Giovanella BC (1992) Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma Xenografts in immunodeficient mice induced by camptothecin. Cancer Res 52: 3980-87.
119. Pantazis P, Mendoza J, DeJesus A, Early J, Shaw M and Giovanella BC (1994c) Development of resistance to 9-nitro-camptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs. Anticancer Drugs 5: 473-9.
120. Perez-Stable C, Shen CC and Shen CKJ (1988) Enrichment and depletion of Hela topoisomerase I recognition sites among specific types of DNA elements. Nucl Acids Res 16: 7975-93.
121. Pessina A (1993) Topoisomerase I in multiple drug resistance. Cytotechnology 12: 127-135.
122. Pommier Y, Kerrigan D and Hartman KD et al. (1990) Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J Biol Chem 265: 9418-22.
123. Pommier Y, Zwelling LA, Kao-Shan CS, Whang-Peng J and Bradley MO (1985) Correlation between intercalator induced DNA strand breaks and sister chromatid exchanges mutations and cytotoxicity in Chinese hamster cells. Cancer Res 45: 314348.
124. Pommier Y, Gupta M, Valenti and Nieves-Neira W (1996) Cellular resistance to camptothecins. In Pantazis P, Giovanella BC and Rothenberg ML (eds) The Camptothecin: From Discovery to the Patient. New York: Annals NY Acad Sci 52: 2268-78.
125. Potmesil M, Hsiang Y-H, Liu LF, Bank B, Grossberg H, Kirschenbaum S, Forlenza TJ, Penziner A, Kanganis D, Knowles D, Traganos F and Silber R (1988) Resistance of human leukemic and normal lynphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48: 3537-3533.
126. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, Avery L and Meyer WH (1994) Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12: 539-43.
127. Priel E, Showalter SD and Blair DG (1991) Inhibition of humanimmunodeficiency virus (HIV-1) replication in vitro by non cytotoxic doses of camptothecin, a topoisomerase I inhibitor. AIDS Res Hum Retrovirus 7: 65-72.
128. Prost S (1995) Mechanisms of resistance to topoisomerases poisons. Gen Pharmacol 26: 1673-84.
129. Qian X and Beck WT (1990) Binding of an optically pure photoaffinity analogue of verapamil LU-49888 to P-glycoprotein from multidrug resistant human leukemic cell lines. Cancer Res 50: 1132-1137.
130. Ray S, Majumder HK, Chakravarty AK, Mukhopadhyay S, Gil RR, and Cordell GA (1996) Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovani. J Nat Prod 59: 27-9.
131. Ray S, Sadhukhan PK, Mandai NB, Mahato SB and Majumder HK (1997) Dual inhibition of DNA topoisomerases of Leishmania donovani by novel indolyl quinolines. Biochem Biophys Res Commun 230: 171-5.
132. Riou JF, Grondard L, Naudin A and Bailly C (1995) Effects of two distamycin-ellipticine hybrid molecules on topoisomerase I and II mediated DNA cleavage: relation to cytotoxicity. Biochem Pharmacol 50: 424-8.
133. Rodriguez-Campos A, Azorin F and Portugal J (1996) Influence of elsamicin A on the activity of mammalian topoisomerase I. Biochemistry 35: 11177-82.
134. Roninson IB (1992) The role of the MDR1 (P-glycoprotein)gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 43: 95-102.
135. Rose KM, Szopa J, Han FS, Cheng YC, Richter A and Scheer U (1988) Association of DNA topoisomerase and RNA polymerase I: a possible role for topoisomerase I in ribosomal gene transcription. Chromosoma 96: 411-416.
136. Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou JF, Antoine E, Cathala G, Brunei C and Tazi J (1996) Specific phosphorylation of S R proteins by mammalian DNA topoisomerase I. Nature 381: 80-2.
137. Rothenberg ML (1997) Topoisomerase I inhibitors. Annu Oncol 8: 837-55.
138. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH and Donehower RC (1992) Phase I and pharmacological study of topotecan: A novel topoisomerase inhibitor. J Clin Oncol 10: 647-56.
139. Rubin E, Pantazis P, Bharti A, Toppmeyer D, Giovanella B and Kufe D (1994) Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-Nitro-camptothecin. J Biol Chem 269: 2433-39.
140. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasi F and Kelsen D (1993) Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors with attempt at dose-intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85: 1499-507.
141. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, DaltonWS, Heijningen van THM, van Kalken CK, Slovak ML, de Vries EGE, van der Valk P, Meijer CJLM and Pinedo HM (1993) Overexpression of a Mr 110 000 vesicular protein in nonP-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-79.
142. Shen CC and Shen CKJ (1990) Specificity and flexibility of therecognition of DNA helical structure by eukaryotic topoisomerase I. J Mol Biol 212: 67-78.
143. Shimizu T and Pommier Y (1996) DNA fragmentation induced by protease activation in p53-null human leukemia cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: Cell-free system studies. Exp Cell Res 226: 292301.
144. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-91.
145. Smith PJ (1990) DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy. Bioassay 12: 1657-72.
146. Snow K and Judd W (1991) Characterization of adriamycin resistant and amsacrine-resistant human leukaemic T-cell lines. Br J Cancer 63: 17-28.
147. Spicer JA, Carriage SA, Atwell GJ, Finlay GJ, Baguley BC and Denny WA (1997) Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 40: 1919-29.
148. Sugarman SM, Zou Y, Wasan K, Poirot K, Kumi R, Reddy S and Perez-Soler R (1996) Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. Cancer Chem Pharmacol 37: 531-8.
149. Sugimoto Y, Tsukahara S, Oh-Hara T, Isoe T and Tsuruo T (1990) Decreased expression of DNA topoisomerase I in camptothecinresistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50: 6925-30.
150. Supino R, Caserini C, Orlandi L, Zaffaroni N, Silvestrini R, Vaglini M and Zunino F (1996) Modulation of melphalan cytotoxic activity in human melanoma cell lines. Anticancer Drugs 7: 604-12.
151. Taniguchi K, Kohno K, Kawanami K, Wada M, Kanematsu T and Kuwano M (1996) Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res 56: 2348-54.
152. Tanizawa A and Pommier Y (1992) Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 52: 1848-54.
153. Tanizawa A, Beitrand R, Kohlhagen G, Tabuchi A, Jenkins J and Pommier Y (1993) Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J Biol Chem 268: 25463-8.
154. Thiebaut T, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC (1987) Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-38.
155. Trask DK and Muller MT (1988) Stabilization of type I topoisomerase DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 85: 1417-25.
156. Trask DK, DiDonato JA and Muller MT (1984) Rapid detection and isolation of covalent DNA protein complexes: application to topoisomerase I and II. EMBO J 3: 671-676.
157. Tsuruo T, Matsuzaki T, Matsushita M, Saito H and Yokokura T (1988) Antitumor effect of CPT-11 a new derivative of camptothecin against pleiotropic drug resistant tumors in vitro and in vivo. Cancer Chemother Pharmac 21: 71-74.
158. Turman MA and Douvas A (1993) A Casein Kinase type II (CKII) like nuclear protein kinase associates with, phosphorylates and activates topoisomerase I. Biochem Med Metab Biol 50: 210225.
159. Valent! M, Nieves-Neira W, Kohlhagen G, Kohn KW, Wall ME, Wani MC and Pommier Y (1997) Novel 7-alkyl methylenedioxycamptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Mol Pharmacol 52: 82-7.
160. van der Zee AG, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse PH, Zijlstra JG and de Vries EG (1991) P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in maglignant tumors of the ovary, before and after platinium/cyclophosphamide chemotherapy. Cancer Res 51: 5915-20.
161. Vasey PA, Jones NA, Jenkins S, Dive C and Brown R (1996) Cisplatin, camptothecin, andtaxol sensitivities of cells withp53associated multidrug resistance. Mol Pharmacol 50: 1536-40.
162. Verweij J, Lund B, Beijnen J, Planting A, de Boer-Dennert M, Koier I, Rosing H and Hansen H (1993) Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4: 673.
163. Vinograd J, Lebowtiz J, Radloff R, Waron R and Laipis P (1965) The twisted circular form of polyoma viral DNA. Proc Natl Acad Sci USA 53: 1104-1111.
164. Wall ME, Wani NC, Cook CE, Palmer KH, McPhail AT and Sim GA (1966) Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkyloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 94: 3888.
165. Wang HK, Liu SY, Hwang KM, Taylor G and Lee KH (1994) Synthesis of novel water-soluble 7-(aminoacylhydrazono)-formyl camptothecins with potent inhibition of DNA topoisomerase I. Bioorg Med Chem 2: 1397-402.
166. Wang HP and Rogler CE (1991) Topoisomerase I-mediated integration of hepadnavirus DNA in vitro. J Virol 65: 2381-92.
167. Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665-697.
168. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65: 636-92.
169. Wang JC (1971) Interaction between DNA and Escherichia coli omega protein. J Mol Biol 55: 523-533.
170. Wang LK, Johnson RK and Hecht SM (1993) Inhibition of topoisomerase I function by nitidine and fagaronine. Chem Res Toxicol 6: 813-8.
171. Wang LK, Rogers BD and Hecht SM (1996) Inhibition of topoisomerase I function by coralyne and 5,6-dihidrocoralyne. Chem Res Toxicol 9: 75-83.
172. Wani MC, Ronman PE, Lindley JT and Wall ME (1980) Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 23: 554-60.
173. Xie G, Gupta R, Atchison K and Lown JW (1996) Bisindolylmaleimides linked to DNA minor groove binding lexitropsins. synthesis, inhibitory activity against topoisomerase I, and biological evaluation. J Med Chem 39: 1049-55.
174. Yang CHJ, Cowan KH and Schneider E (1993) Quantitative PCR for DNA topoisomerase I, II alpha, II beta and mdrl in cell lines and tumor samples. Proc Annu Meet Am Assoc Cancer Res 34:A56.
175. Yang CHJ, Horton JK, Cowan KH and Schneider E (1995) Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 55: 4004-9.
176. Zhang H, Wang JC and Liu LF (1988) Involvement of DNAtopoisomerase I in transcription of human ribosomal RNA genes. Proc Natl Acad Sci USA 85: 1060-1064.
177. Zhang H, D'Arpa P and Liu LF (1990) A model tumor cell killing by topoisomerase poisons. Cancer Cells 2: 23-27.
178. Zhao R, Al-Said NH, Sternbach DL and Lown JW (1997) Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro. J Med Chem 40: 216-25.
179. Zhou BS, Bastow KF and Cheng YC (1989) Characterization of 3′-region of the human DNA topoisomerase I gene. Cancer Res 49: 3922-3927.
180. Zijlstra JG, De Jong S, De Vries EGE and Mulder NH (1990) Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother 7: 11-18.